Vyvgart (efgartigimod alfa) is generally well tolerated and effective for adults with generalized myasthenia gravis (gMG), regardless of the presence and type of disease-causing antibody, according to a real-world study in Japan. The treatment, which has been approved in Japan for gMG regardless of antibody status since 2022 and…
News
A prefilled syringe and an autoinjector used to deliver gefurulimab, an experimental therapy in late-stage development for generalized myasthenia gravis (gMG), can be safely and effectively used by most gMG patients, caregivers, and healthcare professionals. That’s according to a simulated-use study, which aims to assess if people can…
Satisfaction with treatment doesn’t necessarily affect whether people with myasthenia gravis (MG) take their medications as directed, according to a new study that surveyed nearly 100 patients at a center in China. Findings also indicate that people living with MG who are older are less likely to take their…
Researchers called for standardized guidelines for diagnosing and treating people with myasthenia gravis (MG) who test negative for typical disease-driving antibodies. A review study showed that antibody-negative MG tends to manifest earlier than antibody-positive disease, and a substantial portion of antibody-negative patients do not respond adequately to standard immune-suppressing…
Ongoing symptoms that persist despite treatment can disrupt daily life, work, and mental well-being among adults with generalized myasthenia gravis (gMG), according to the BEYOND study. When study participants rated how strongly they agreed with statements about how these ongoing symptoms affect their everyday lives, the statement — “If…
Biologic therapies were associated with less steroid use and greater muscle strength than treatment with standard care among people recovering from a myasthenic crisis, a potentially life-threatening complication of myasthenia gravis (MG), a new study from China suggests. Data showed that six months after leaving the hospital, individuals…
The Myasthenia Gravis News forums welcomed Jenny McCue, vice president of research and clinical development at the Myasthenia Gravis Foundation of America (MGFA), for an hour-long Q&A earlier this month. Forum members had an opportunity to ask questions in real time about the latest in myasthenia gravis…
Most neurologists believe that CAR T-cell treatments have the potential to revolutionize care for neuro-immune diseases such as myasthenia gravis (MG), but hopes are tempered by still-unanswered questions about their safety and long-term impact. That’s according to a survey of 92 neurologists in the U.S. conducted last month by…
Myasthenia gravis (MG) can have a substantial impact on a person’s quality of life, but currently available data make it hard to nail down a number that can represent the average impact of the disease in standard health economic models, a review study showed. Score estimates in the EuroQol…
Adults with late-onset myasthenia gravis (LOMG), when symptoms begin at age 50 or later, showed advanced fatty replacement of the thymus gland, while a separate group of LOMG patients showed reduced production of new immune cells, according to a new study. Abnormalities in the thymus gland are well established…
Recent Posts
- Real-world data show gMG treatment works across patient groups
- Myasthenia gravis is more than the list of its symptoms
- gMG patients can safely use self-injectors for experimental therapy
- Treatment satisfaction may not alter adherence in MG, study suggests
- When I could no longer be a summer person, fall made room for me